Navigation Links
Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
Date:10/31/2007

COLUMBIA, Mo. Heart disease is the leading cause of death in the United States and greatly affects the quality and length of life for individuals with specific forms of muscular dystrophy. Recent discoveries have demonstrated that gene and/or stem cell therapy could help a variety of organs in the body, but until now scientists have been unsure whether the heart could benefit from these treatments. According to a new study, recently published in Circulation Research, a journal of the American Heart Association, University of Missouri-Columbia researchers have demonstrated that a muscular dystrophy patient should be able to maintain a normal lifestyle if only 50 percent of the cells of the heart are healthy.

Patients with Duchenne muscular dystrophy and Becker muscular dystrophy have a gene mutation that disrupts the production of a protein known as dystrophin. Absence of this protein starts a chain reaction that eventually leads to muscle cell degeneration and death. Eventually, the damaged muscle tissue is replaced by fibrous, bony or fatty tissue and loses function. In the heart, this leads to severe heart disease and can place severe limitations on individuals afflicted with the disease.

In the past, scientists believed that the only way to have a healthy heart was to rid the heart of all damaged tissue. The heart is considered to be a synchronized organ; therefore, it was believed that the heart needed to maintain 100 percent normal cells in order to stay healthy.

In gene therapy, mutated genes are replaced with healthy genes. In stem cell therapy, diseased cells are replaced with healthy cells. However, in these gene and stem cell therapies, it is not feasible to fix every cell in the heart. Previously, scientists were uncertain whether partial correction could benefit patients.

In our study, we found that a heart with 50 percent normal cells looks like a normal heart, said Dongsheng Duan, an associate professor of mo
'/>"/>

Contact: Christian Basi
BasiC@missouri.edu
573-882-4430
University of Missouri-Columbia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Silence the gene, save the cell: RNA interference as promising therapy for ALS
2. Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers
3. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
4. Columbia research lifts major hurdle to gene therapy for cancer
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Gene therapy converts dead bone graft to new, living tissue
7. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. Gene Therapy For Parkinsons Disease Moves Forward In Animals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...may be used to boost resistance to, or slow, the d...Medicine researchers report in a study published i... , Parkinson,s disease is caused by a degenerati...known as the substantia nigra, which is responsibl...dopamine in late-stage Parkinson,s causes symptoms...
(Date:11/25/2009)...ps some 250 million liters of blood through the bo...the heart have to be extremely durable. The resear...air of the Department of Medicine III at Heidelber...atus), has discovered a protein that is responsibl... the sarcomere. In cooperation with other research...
(Date:11/24/2009)...standing how sounds associated with Navy sonar mig...ey hear it at all. , The same type of large indu...ct flaws in the space shuttle,s behemoth solid fue...e the giant head of a whale. The scans are providi...s hearing anatomy using a breakthrough method deve...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Rocket science leads to new whale discovery 2Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 1Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 2Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 3Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 4Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 5Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer 5034 1Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer 5034 2Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer 5034 3Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer 5034 4Study reveals 2 3 of prostate cancer patients do not need treatment 58130 1Study reveals 2 3 of prostate cancer patients do not need treatment 58130 2
...out of the Ireland Cancer Center of University Hos... majority of triple negative breast cancers expres..., presented today at the San Antonio Breast Cancer...ine trial for patients with early stage triple neg... recurrence of this aggressive type of breast canc...
...lable in Spanish . , , The conditioning Works o...amount of vegetable species. The researchers of th...aged to grow in the laboratory two native bushy sp...able cover restoration. They will try to use them ... of Sierra Nevada . , The vegetable species of Si...
...ilable in French . , A novel x-ray technique al...me scale never reached before has been developed b...errer Institute (PSI) in Switzerland. Results of t...f EPFL,s laboratory of Ultrafast Spectroscopy in c...line December 11 in the journal Science . , This...
Other Biology News:Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target 2An essay proves that vegetation could recover in the ski resort of Sierra Nevada 2Molecules in the spotlight 2
(Date:11/24/2009)...employment grew by 29,000 jobs in October, and th...owth during the U.S. recession. However, clinics a...th systems are coming closer to having to actually...tors. , (Vocus) November ...ng in October despite the shedding of jobs in most...
(Date:11/24/2009)...re-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),abiop...alizingnovelpainmanagementtherapies,announcedtoday...er,isscheduledtopresentatthe21stAnnualPiperJaffray...NewYorkPalaceHotelinNewYork,NewYork. ,, Mr.DiTo...eavailabletorespondtoquestionsduringthepresentatio...
(Date:11/24/2009)...tly approved the Promega PowerPlex 16 HS System fo...ng DNA records for the National DNA Index System. ... -- The FBI recently approved the Promega PowerPl...icipating in, or generating DNA records for, the N...ntains more than seven million profiles and has as...
(Date:11/24/2009)...rstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglo...edthatithassubmittedaMAAtotheEuropeanMedicinesAgen...enttherapyindevelopment,forthetreatmentofType1Gauc...elaglucerasealfathathasbeensubmitted,withprevious,...donaglobalsupplyshortageofthecurrentlyapprovedandm...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...ts for the Product,TopoTarget Successfully Buys Ba... the Global Rights for the Product ... Corporation, COPENHAGEN, April 22 , - Deal Cove..., a Total,of 5 Million TopoTarget Shares and a Com...all to be Held 2pm CET, TopoTarget A/S (OMX: TOPO...
...Ortho Evra is an adhesive,transdermal birth contro...lgestromin and 20 mcg of ethinyl estradiol into th...week for three weeks, and no patch is worn,during ...A in November,2001, and over 4 million women have ...tinues to be marketed aggressively to both consume...
.../PRNewswire-FirstCall/-- Pharmacyclics,Inc. (Nasda...aq staff,deficiency letter on April 17, 2008 indic...bid price for Pharmacyclics, common stock has clos...1.00 per share for continued,inclusion on The Nasd.... In,accordance with Marketplace Rule 4450(e)(2), ...
Other Biology Technology:TopoTarget Successfully Buys Back Full Control of Belinostat 2TopoTarget Successfully Buys Back Full Control of Belinostat 3TopoTarget Successfully Buys Back Full Control of Belinostat 4TopoTarget Successfully Buys Back Full Control of Belinostat 5TopoTarget Successfully Buys Back Full Control of Belinostat 6TopoTarget Successfully Buys Back Full Control of Belinostat 7Ortho Evra Patch Makers Settling Cases 2
Anti-Taste Receptor 2 (TR2) Polyclonal Antibody, Unconjugated from CHEMICON
Anti-Latanoprost (EIA Antiserum) Antibody, Unconjugated from Cayman Chemical
Anti-SEK1 / MKK4, phospho (Thr261) Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-BACE/Asp2 (CT) Polyclonal Antibody, Unconjugated from Assay Designs/Stressgen Bioreagents
Biology Products: